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Abstract
Surgical archives of tumor specimens are often impure. The
presence of RNA transcripts fromnontumor cells, such as immune
and stromal cells, can impede analyses of cancer expression
proﬁles. To systematically analyze the impact of tumor purity,
the gene expression proﬁles and tumor purities were obtained for
7,794 tumor specimens across 21 tumor types (available in The
Cancer Genome Atlas consortium). First, we observed that genes
with roles in immunity and oxidative phosphorylation were
signiﬁcantly inversely correlated and correlated with the tumor
purity, respectively. The expression of genes implicated in immu-
notherapy and speciﬁc immune cell genes, along with the abun-
dance of immune cell inﬁltrates, was substantially inversely
correlated with tumor purity. This relationship may explain the
correlation between immune gene expression and mutation bur-
den, highlighting the need to account for tumor purity in the
evaluation of expression markers obtained from bulk tumor
transcriptome data. Second, examination of cluster membership
of gene pairs, with or without controlling for tumor purity,
revealed that tumor purity may have a substantial impact on
gene clustering across tumor types. Third, feature genes formolec-
ular taxonomy were analyzed for correlation with tumor purity,
and for some tumor types, feature genes representing the mesen-
chymal and classical subtypes were inversely correlated and
correlated with tumor purity, respectively. Our ﬁndings indicate
that tumor purity is an important confounder in evaluating the
correlation between gene expression and clinicopathologic fea-
tures such as mutation burden, as well as gene clustering and
molecular taxonomy. Cancer Immunol Res; 6(1); 87–97. 2017 AACR.
Introduction
Solid tumor tissues are comprised of cellular components
originating from various types of cancerous and noncancerous
tissues, the latter including immune, stromal, endothelial, and
epithelial cells (1). Such noncancerous cells are regarded as
common contaminants in tumor admixtures and constitute a
substantial fraction of tumor masses. They are also important in
carcinogenesis. Stromal or mesenchymal cells may enhance
tumor growth and inﬂuence the response of cancers (2), whereas
immune cells, such as tumor inﬁltrating cytotoxic T lymphocytes,
may inhibit tumor growth (3, 4). The extent of nontumor cell
contamination or tumor purity (the proportion of tumor cells in
the mixture) can be estimated by histologic examination or
computational methods using various genomic resources (5,
6). Standard tumor sampling using surgical specimens may
achieve a tumor purity that exceeds 70%, but it can often be
lower, leading to systematic biases in tumor genome analyses (5).
This contamination can complicate tumor transcriptome analyses
due to the cancermasses representing amixture of RNA transcripts
originating from tumor cells andnoncancerous cells.On the other
hand, reports state that the impurity of tumors can be leveraged
for immunologic insights (7, 8). In these studies, the relative
proportion of tumor-inﬁltrating lymphocytes and other immune
cells can be estimated from the tumor transcriptome by decon-
volution methods.
Cancer transcriptome analyses, especially those focused on
immune-related genes, must take into account the tumor purity
because immune cells are a major fraction of noncancerous cells
in the tumor mass. However, the impact of tumor purity on the
expression of immune-related genes remains unclear. Immune
checkpoint blockade using monoclonal antibodies against cyto-
toxic T lymphocyte–associated protein 4 (CTLA-4; ref. 9) and
programmed cell death protein 1/programmed death-ligand 1
(PD-1/PD-L1; ref. 10) produces durable clinical responses for a
number of solid tumors including melanoma (11) and non–
small cell lung cancer (12). The remarkable success rate of clinical
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trials utilizing this approach is tempered by the reality that only a
fraction of patients will respond to the treatment. Thus, a need
exists to identify biomarkers that can select patients with a better
chance of achieving clinical beneﬁts with cancer immunotherapy.
The mutation burden of tumor genomes is considered a reliable
predictor for the response to immunotherapy (9, 10, 13). Along
with the somatic mutations that may produce neoepitopes elicit-
ing antitumor T cell–mediated responses (14), the expression of
immune genes for the targets or proxies of immunotherapy (e.g.,
CTLA-4 and PD-1/PD-L1) has been proposed (15–18). Other
expression-basedmarkers representing the activity of tumor-inﬁl-
trating T lymphocytes, such as granzyme A (encoded by GZMA),
perforin-1 (encoded by PRF1; ref. 19), and CD8a (encoded by
CD8A; ref. 20), may also be potentially useful as predictive
markers for immunotherapy. The expression of such immune-
related genes originating fromnoncancerous immune cells can be
associated with the tumor purity. The differential expression
between tumor and nontumor tissues may be biased, as demon-
strated for immune-related genes such as those encoding CTLA-4
and its ligand, CD86 (5).
An early study on tumor purity has reported the potential
inﬂuence of the tumor purity on the coexpression network,
clustering-based tumor subtyping or molecular taxonomy, and
the identiﬁcation of differentially expressed genes (5). This study
demonstrated that the coexpressed gene pairs often arise merely
due to the tumor purity, highlighting the need for purity adjust-
ment. However, it is largely unknown which gene pairs or tumor
types are subject to purity adjustment and how to estimate the
impact of tumor purity on gene clustering. Aran and colleagues
showed that the certain tumor subtypes, such as mesenchymal
subtypes of malignant brain tumors, were characterized by low
purity, and the correlation of the feature gene expression with
tumor purity showed a bimodal distribution (5). Similar reports
have been published suggesting that the expression-based molec-
ular taxonomy and risk assessment can be biased by tumor purity
(21), and the expression signals representingmesenchymal tumor
subtypes have been attributed mainly to stromal cells instead of
tumor cells (22, 23).
In this study, we scrutinized the large PanCancer transcrip-
tome database containing 7,794 tumor specimens and 21
tumor types from The Cancer Genome Atlas (TCGA) consor-
tium. Tumor purity for the corresponding tumor samples was
obtained in a PanCancer tumor purity study (5). Three aspects
of cancer transcriptome analyses were investigated for the
potential impact of tumor purity—the correlation of tumor
purity with individual genes (especially those related to
immunity), gene clustering, and molecular taxonomy.
Although purity has been previously evaluated as a potential
confounding factor in gene expression analyses (5), we further
investigated the impact of tumor purity adjustment on the
correlation between the expression of genes, including known
immune markers and mutation burden. We also evaluated the
impact of tumor purity on gene clustering and observed that a
substantial number of gene pairs lost their cluster member-
ship concordance after purity adjustment, and the extent was
variable across tumor types. A substantial inverse correlation
or correlation with tumor purity was observed for feature
genes, such as those representing mesenchymal or classic
tumor subtypes, suggesting that tumor purity also represents
a major confounding factor in expression-based molecular
taxonomy.
Methods and Materials
Datasets
We obtained RNA sequencing (RNA-seq)–based gene expres-
sion proﬁles of 7,794 tumor specimens across 21 tumor types
from the TCGA pan-cancer consortium (https://cancergenome.
nih.gov/). The tumor types examined included 79 adenocortical
carcinoma (ACC), 408 bladder urothelial carcinoma (BLCA),
1,100 breast invasive carcinoma (BRCA), 306 cervical and endo-
cervical carcinoma (CESC), 287 colon adenocarcinoma (COAD),
166 glioblastoma multiforme (GBM), 522 head and neck squa-
mous cell carcinoma (HNSC), 66 kidney chromophobe (KICH),
534 kidney renal clear cell carcinoma (KIRC), 291 kidney renal
papillary cell carcinoma (KIRP), 530 lower grade glioma (LGG),
373 liver hepatocellular carcinoma (LIHC), 517 lung adenocar-
cinoma (LUAD), 501 lung squamous cell carcinoma (LUSC), 307
ovarian serous cystadenocarcinoma (OV), 498 pancreatic adeno-
carcinoma (PRAD), 95 rectumadenocarcinoma (READ), 471 skin
cutaneous melanom (SKCM), 509 thyroid carcinoma (THCA),
177 uterine corpus endometrial carcinoma (UCEC), and 57
uterine carcinosarcoma (UCS). We also obtained tumor purity
for these selected cases as themedian of four types of tumor purity
estimated from different histologic or genomic resources, as
previously used as a consensus purity measure (5).
Resource for immune cell inﬁltrates and mutation burdens
Marker genes representing 20 immune cell types were obtained
from a list of commercial gene panel (nCounter Human Pan-
Cancer Immune Proﬁling Panel; NanoString Technologies). Per
immune cell type, three to eight representative, immune-related
geneswere selected from thepanel gene list and their expression in
TCGA specimens were investigated for correlation with tumor
purity. We also obtained the relative abundance of immune cell
inﬁltrates for individual TCGA tumor specimens as estimated by
two deconvolution algorithms, TIMER (7) and CIBERSORT (8).
To correlate gene expression with the burdens of somatic muta-
tion and predicted neoantigens, we used the expression proﬁles of
3,588 tumor specimens, for which the number of neoantigens has
been predicted (19). For somatic mutations, we calculated the
natural or unadjusted correlation between the expression of all
the genes examined and the mutation abundance, as well as the
partial correlation controlling for the tumor purity. We then
focused on known immune genesGZMA, PRF1, PDCD1 (encodes
PD-1), CD274 (encodes PD-L1), CTLA4, and CD8A, as well as
genes related with mutation abundance such as APOBEC3B and
MLH1. In case of MLH1, the correlation with tumor purity was
calculated across three tumor types with frequent microsatellite
instability (COAD, STAD, andUCEC).CYT (cytolytic activity)was
calculated as the geometric mean of GZMA and PRF1 expression,
as previously indicated (19). All statistical analyses were done
using R software (https://www.r-project.org/) unless speciﬁed
otherwise.
Gene set enrichment analysis
To identify the molecular functions enriched in the tumor
purity-correlated and -inversely correlated genes, we used a pre-
ranked version of a gene set enrichment analysis (GSEA; ref. 24).
For all the genes examined, Spearman correlationswere calculated
between their expression and tumor purity to generate a ranked
list of genes. The pre-ranked version ofGSEAwas performed using
the Gene Ontology terms (MSigDB, c5 category; http://software.
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broadinstitute.org/gsea/msigdb) or c2cp category (curated path-
ways) as functional gene sets. GSEA was also used to measure the
extent of enrichment for feature genes toward correlation or
inverse correlation with tumor purity.
Survival analysis
Per tumor type, Kaplan–Meier survival curves were generated
by partitioning the patients into high and low CYT gene expres-
sion using the median. Log-rank test was used to estimate the
signiﬁcance of survival between patients with high and low CYT
expression. To control for the tumor purity, Kaplan–Meier sur-
vival curves were also generated using the residual of CYT expres-
sion after linear regression against the tumor purity. The residuals
were also used to evaluate the association between purity-adjust-
ed CYT and survival by log-rank tests. P < 0.05 was signiﬁcant.
Purity-adjusted gene clustering
For each tumor type, we ﬁrst identiﬁed a subset of genes with
variable expression (i.e., 5,000 genes with top median absolute
deviation) and assigned them into six gene clusters by consensus
clustering (25). The number of gene clusters for consensus clus-
tering (k ¼ 6) was determined by the manual examination of
consensus cumulative distribution function plots across the
tumor types. Using the results of purity-unadjusted gene cluster-
ing, we discriminated the possible gene pairs into CM and CMM
pairs (cluster-matched and cluster-mismatched, respectively)
according to cluster membership of genes in the pairs. For puri-
ty-adjusted gene clustering, a gene-wise distance matrix was
generated using the value of 1  correlation (partial Spearman
correlation between the expression of two genes in a given pair
controlled for the tumor purity) as a distance measure. The ppcor
R package (26) was used to calculate partial correlation by
controlling for the tumor purity. Using the results of purity-
adjusted gene clustering, CM and CMM gene pairs were further
discriminated into CM-C/CMM-C (C for "concordant") and CM-
D/CMM-D (D for "discordant"). For example, if two genes in a
pair belong to the same cluster, the corresponding genepair isCM.
The CM gene pairs were further annotated as CM-C if the two
genes in the pair fell into the same cluster after purity adjustment
or, otherwise annotated asCM-D.CMM-CandCMM-Dgenepairs
were annotated similarly. We obtained 39,240 protein–protein
interaction (PPI) gene pairs from public database of HPRD
(Human Protein Reference Database; ref. 27). The relative abun-
dance of PPI gene pairs was calculated across the four categories of
gene pairs.
Selection of feature genes
For GBM, we obtained 840 feature genes that were used to
classify the TCGA GBM cases into four subtypes (proneural,
neural, classic, and mesenchymal; ref. 28). Four subtype-speciﬁc
GBMfeature genesweremeasured for their correlationwith tumor
purity using pre-ranked GSEA (24). To demonstrate the impact of
tumor purity on GBM molecular taxonomy, the feature genes
were partitioned into 400 purity-correlated and 400 purity-
inversely correlated genes. The 173 GBM cases with annotated
subtypes were subject to hierarchical clustering using these two
subsets of feature genes. Hierarchical clustering was done using 1
 Pearson correlation as distance with average linkage.We further
obtained the tumor subtypes for additional ﬁve tumor types
(BRCA, COAD, HNSC, LUAD, and LUSC). To identify the feature
genes in each tumor type, we used ClaNC R package (29). The
number of feature genes was determined as the smallest number
of genes with the lowest cross-validation and prediction error as
reported by ClaNC. The extent of correlation with tumor purity
was evaluated for individual sets of feature genes per tumor type
by pre-ranked GSEA.
Results
Relationship between tumor purity and gene expression
We ﬁrst examined the correlation between gene expression
and tumor purity (Fig. 1A). Spearman correlation (r) was
calculated for the expression of individual genes and tumor
purity across 7,794 tumors encompassing 21 tumor types. A
tendency of negatively skewed distribution of the correlation
coefﬁcients suggested that the expression of many genes was
inversely correlated with tumor purity. GSEA was done to
identify molecular functions enriched with genes that were
correlated or inversely correlated with tumor purity (Table 1).
Mitochondria- and immune-related molecular terms (MSigDB
c5 Gene Ontology or GO categories) were correlated and
inversely correlated with tumor purity, respectively. Similar
molecular terms such as "respiratory electron transport" and
"cytokine-cytokine receptor interaction" were identiﬁed using
other functional gene sets (MSigDB c2cp as Curated Path-
ways; Supplementary Table S1). The correlation of the genes
belonging to the top 10 correlated or inversely correlated
molecular functions are shown in Fig. 1B (n ¼ 175 and
1,140 genes as aggregates of genes in 10 mitochondria- and
10 immune-related GO categories in Table 1 as red and blue,
respectively) and suggests that immune-related genes comprise
a major fraction of genes at the skewed edge of the distribution
of the genes that were inversely correlated with tumor purity.
We counted the number of occurrences in 10 immune-related
GO categories listed in Table 1 for the 1,140 immune-related
genes in Fig. 1B. The genes with a higher number of calls in the
10 immune-related GO categories were inversely correlated to
a greater extent with the tumor purity than those with a lower
number of calls (Supplementary Fig. S1).
Because the tumor purity used in this study was mainly the
consensus of purity estimates from multiple genomic and path-
ologic resources (5), the same analyses were done on four types of
tumor purities from different genomic resources or histology
(copy number, gene expression, DNA methylation, and patho-
logic examination). We consistently observed enrichment of
immune-related genes toward the inverse correlation with tumor
purity, regardless of the genomic resource to estimate that tumor
purity (Supplementary Fig. S2). We also examined the relation-
ship between gene expression and tumor purity for individual
tumor types. The distribution of correlation coefﬁcients was
similar across the 21 tumor types (Supplementary Fig. S3).
Although the immune-related genes were consistently enriched
in genes inversely correlated with tumor purity across the 21
tumor types (Supplementary Table S2), the genes correlated with
tumor purity across tumor types were enriched for diverse molec-
ular functions: oxidative phosphorylation/mitochondria-related
genes for BRCA, KIRC, LIHC, PRAD, and THCA tumors; ribo-
some/translation-related genes for COAD, HNSC, KICH, LUAD,
READ, UCEC, SKCM, UCEC, and UCS tumors; chromosome/
DNA replication-related genes for ACC, GBM, and LUSC tumors;
histone methylation-related genes for BRCA tumors; cilium/
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Figure 1.
The inverse correlation of immune-related genes with tumor purity. A, The distribution of correlation coefﬁcients (p, Spearman correlation) between the gene
expression and tumor purity is shown. B, The correlation coefﬁcients is shown in a histogram for the selected immune- and mitochondria-related genes.
Immune: 1,140 genes, red bars; mitochondria: 175 genes, blue bars. C, Scatter plots show the expression of genes and tumor purity (y and x-axes, respectively) for six
immune marker genes selected. The expression levels are shown in log2 scale. D, Three to eight genes representing 20 immune cell types were selected, and
correlationwith tumor purity is shown. E, The correlationwith tumor purity is shown for the abundance of six immune cell inﬁltrates as estimated by TIMER algorithm
in a heatmap. Top row (total): the correlation measured across the total dataset and the correlation for individual tumor types are shown below. A color
indicator shows the level of correlation with tumor purity. F, Correlation with tumor purity for 22 types of immune inﬁltrates whose abundance was measured by
CIBERSORT algorithm. The annotation of immune cell inﬁltrates is according to the output of the used algorithms.
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motility-related genes for CESC, KIRP, and OV tumors; and
glutamate receptor-related genes for LGG tumors.
Next, we selected six immune markers, including genes
encoding cytotoxic T lymphocyte differentiation markers (gran-
zyme A, perforin, and CD8a) and genes encoding multiple
immunosuppressive checkpoints (PD-1, PD-L1, and CTLA-4)
as targets of immunotherapy (4, 19). The expression of these
genes was inversely correlated with tumor purity (r < 0.5; P <
2.2  1016; Fig. 1C). For correlations of speciﬁc immune cells,
we further selected known marker genes for 20 immune cell
types. Figure 1D shows the distribution of correlations with the
tumor purity for three to eight marker genes per immune cell
type (the list of marker genes is available in Supplementary
Table S3). Most of the marker genes for particular immune cell
types were inversely correlated with tumor purity (r < 0 for 89
genes out of 100 immune cell marker genes selected). Those
representing dendritic cells, B cells, T cells, and cytotoxic cells
were the most inversely correlated (median of r < 0.5). The
inverse correlation for the genes representing memory T cells
and natural killer cells was observed to a lesser extent. Because
investigation based on a small number of genes may be subject
to a selection bias, we further investigated the relative abun-
dance of immune cell ﬁltrates measured by expression-based
deconvolution for their correlation with tumor purity. Figure
1E shows a heatmap representing the correlations between the
abundance of six immune cell inﬁltrates (B cells, CD4þ and
CD8þ T cells, neutrophils, macrophages, and dendritic cells, as
estimated by TIMER algorithm; ref. 7) and tumor purity.
Overall, inverse correlations with tumor purity were observed
for the majority of immune cell inﬁltrates across tumor types
(98.1% of correlations were inverse correlations, r < 0). This
was also true for the abundance of 22 types of immune cells, as
estimated by CIBERSORT algorithm (8), where 88.3% of cor-
relations were inverse correlations (Fig. 1F). Substantial inverse
correlation was observed for CD8þ T cells and M2 macro-
phages. These results indicate that the immune-related molec-
ular functions represent the major functional category whose
member genes are inversely correlated with tumor purity,
which is also true for known immune marker genes and the
relative abundance of immune cell inﬁltrates.
Immune marker gene expression and mutation burden
To examine the impact of tumor purity on the expression of
immune genes, we focused on the previously reported corre-
lation between the immune marker gene expression and
mutation burden (19). Consistent with the previous report,
an expression-based measure of cytotoxic T lymphocytes
inﬁltrates, CYT (cytolytic activity, a geometric mean of GZMA
and PRF1 expression), was signiﬁcantly correlated with the
mutation burden (r ¼ 0.19, P < 2.2  10–16; Fig. 2A).
However, these two parameters (CYT and mutation abun-
dance) were also signiﬁcantly inversely correlated with tu-
mor purity (r ¼ 0.70 and 0.20, respectively; both P < 2.2 
10–16; Fig. 2B and C), suggesting that the correlation between
CYT and mutation burdens may have come from their rela-
tionship with the tumor purity. The abundance of predicted
neoantigens was signiﬁcantly correlated with the mutation
abundance (r ¼ 0.90, Supplementary Fig. S4A). As expected,
substantial inverse correlation and correlation were observ-
ed between the number of neoantigens with tumor purity
(r ¼ 0.21, Supplementary Fig. S4B) and with CYT (r ¼ 0.19,
Supplementary Fig. S4C), respectively. These ﬁndings suggest
that the previously reported correlation between CYT and the
burdens of somatic mutation or neoantigens (19) may
likely result from the correlation of these features with tumor
purity.
To further investigate the impact of tumor purity on the
observed correlation between gene expression and mutation
burdens, we applied partial correlations to control for tumor
purity (5). For the comparison, we calculated two types of
correlation—the expression of all the genes and mutation bur-
dens with or without controlling for tumor purity (adjusted and
unadjusted/natural correlation, respectively). A scatter plot of the
distribution of the two types of correlations for all genes (purity-
adjusted and -unadjusted/natural correlation for y- and x-axes,
respectively; Fig. 2D) revealed that these two correlations were
Table 1. Molecular functions correlated or inversely correlated with tumor purity
Correlation Functions (MSigDB c5, GO categories) Genes ES NES P value FDR FWER
Correlated GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_ASSEMBLY 74 0.7 2.9 0 0 0
GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I_ASSEMBLY 55 0.6 2.8 0 0 0
GO_NADH_DEHYDROGENASE_COMPLEX_ASSEMBLY 55 0.6 2.8 0 0 0
GO_NADH_DEHYDROGENASE_COMPLEX 42 0.7 2.8 0 0 0
GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I_BIOGENESIS 55 0.6 2.8 0 0 0
GO_MITOCHONDRIAL_ELECTRON_TRANSPORT_NADH_TO_UBIQUINONE 41 0.7 2.7 0 0 0
GO_INNER_MITOCHONDRIAL_MEMBRANE_PROTEIN_COMPLEX 101 0.6 2.7 0 0 0
GO_RESPIRATORY_CHAIN 78 0.6 2.6 0 0 0
GO_NADH_DEHYDROGENASE_ACTIVITY 37 0.7 2.6 0 0 0
GO_MITOCHONDRIAL_PROTEIN_COMPLEX 131 0.5 2.6 0 0 0
Inversely correlated GO_ADAPTIVE_IMMUNE_RESPONSE 252 0.8 3.1 0 0 0
GO_CELLULAR_RESPONSE_TO_INTERFERON_GAMMA 119 0.8 3.0 0 0 0
GO_RESPONSE_TO_INTERFERON_GAMMA 141 0.8 3.0 0 0 0
GO_REGULATION_OF_INTERFERON_GAMMA_PRODUCTION 93 0.8 3.0 0 0 0
GO_POSITIVE_REGULATION_OF_CELL_ACTIVATION 284 0.7 2.9 0 0 0
GO_REGULATION_OF_LEUKOCYTE_PROLIFERATION 202 0.7 2.9 0 0 0
GO_REGULATION_OF_T_CELL_PROLIFERATION 144 0.8 2.9 0 0 0
GO_INFLAMMATORY_RESPONSE 445 0.7 2.9 0 0 0
GO_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION 365 0.7 2.9 0 0 0
GO_REGULATION_OF_LEUKOCYTE_MEDIATED_IMMUNITY 155 0.8 2.9 0 0 0
NOTE: ES, NES, FDR, and FWER are enrichment score, normalized ES, false discovery rate, and family-wise error rate, respectively.
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concordant with each other. To identify the molecular functions
enriched with genes whose correlation with mutation abundance
is subject to controlling for tumor purity, we performed GSEA,
using the differential between the purity-adjusted and -unadjust-
ed correlations as a rank metric with GO categories. Mitochon-
dria- and immune-related molecular functions, which were iden-
tiﬁed as molecular functions enriched with genes correlated and
inversely correlated with tumor purity (Table 1), were also
enriched with genes whose correlation with mutation abundance
became higher and lower after controlling for the tumor purity,
respectively (Supplementary Table S4). Fig. 2D also shows 175
mitochondria- and 1,140 immune-related genes (from Fig. 1B) in
red and blue dots, respectively, to demonstrate that mitochon-
dria- and immune-related genes comprise major functional cat-
egorieswhose correlationwithmutation abundance are subject to
or not subject to controlling for the tumor purity. Figure 2E shows
that the positive correlation coefﬁcients withmutation burdens of
six immune genes (GZMA, PRF1, CD8A, PDCD1, CD274, and
CTLA4) diminished after purity adjustment. We also examined
the correlation with the mutation burdens for APOBEC3B and
MLH1. The activity of spontaneous cytidine deaminase, APO-
BEC3B, has been associatedwith elevatedmutation rates in breast
cancer and other tumor types (30), and the loss of MLH1 activity
by promoter hypermethylation is associated with mutator phe-
notypes in some tumor types (31). As expected, a correlation and
inverse correlation with the mutation abundance were observed
for APOBEC3B and MLH1, respectively (for MLH1, correlation
was measured in COAD, STAD, and UCEC tumor types; Fig. 2E).
The correlation of APOBEC3B and inverse correlation of MLH1
expression with mutation abundance were also affected by con-
trolling for tumor purity but to a lesser extent compared with
immunemarker genes. These results suggest that using the expres-
sion of individual genes as markers for mutation abundance may
be biased by tumor purity and requires caution, especially for
immune-related genes.
Previous analyses reported that CYT gene expression is mar-
ginally associated with patient prognosis, in terms of overall
survival (19). We further investigated the association between
patient survival and CYT gene expression with or without con-
trolling for the tumorpurity. Signiﬁcant association (P<0.05)was
observed for BRCA, LGG, LIHC, and SKCM (Supplementary Fig.
S5A), but after controlling for the tumor purity, BLCA showed
Figure 2.
Relationship between the expression of immune-related genes and burdens of somatic mutation.A, Scatter plot showing CYT (a geometric mean ofGZMA and PRF1
expression; x-axis in log2 scale) and the number of somaticmutations (y-axis; log2 scale). Correlation coefﬁcient (r¼0.19) and a trendline are indicated.B andC, Two
scatter plots show correlation of tumor purity with CYT and mutation burdens (r ¼ 0.70 and 0.20, respectively). Signiﬁcance was calculated using R
software. D, Scatter plot of the correlation coefﬁcients between gene expression and mutation burdens calculated with or without controlling for the tumor purity
(y- and x-axes, respectively). Mitochondria: 175 genes, red dots; immune: 1,140 genes, blue dots (as in Fig. 1B). E, Purity-adjusted (yellow) and -unadjusted
(green) correlations for the expression of immunemarker genes (GZMA, PRF1, PDCD1, CD274, CTLA4, andCD8A) aswell asAPOBEC3B andMLH1with the burdens of
somatic mutation. MLH1: the correlation was measured for three tumor types of COAD, STAD, and UCEC.
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signiﬁcant association between CYT gene expression and patient
survival (Supplementary Fig. S5B). Previously, a study reported
that tumor purity is associated with patient survival for LGG (5).
Thus, it is reasonable to speculate that the signiﬁcant association
between CYT gene expression and survival may be attributed to
their relationship with tumor purity, at least for this tumor type.
The discrepancy of the CYT–survival relationship in other tumor
typesmaynot be simply explained by tumor purity, but the tumor
purity should be taken into account as a potential confounding
factor in correlation analyses between clinicopathologic features,
such as patient survival and expression of immune genes, such as
GMZA and PRF1.
Impact of tumor purity on gene clustering
Previous investigation of the impact of tumor purity on coex-
pression analyses revealed that a substantial number of coex-
pressed gene pairs may have arisen due to their relationship with
tumor purity, raising a need to account for the tumor purity in
coexpression analyses (5). They also examined coexpressed gene
clusters for their enriched molecular functions and the extent of
correlation with the purity (5). We further examined the cluster
membership of gene pairs andmeasured their coherence between
gene clusters with or without controlling for tumor purity. For
each tumor type, we ﬁrst selected 5,000 highly variable genes and
assigned them into6 gene clusters by consensus clustering (purity-
unadjusted). Individual gene pairs were classiﬁed into cluster-
matched pairs (CM pairs) as genes in the pair belonging to the
same cluster and cluster-mismatched pairs (CMM pairs) for
others. The proportion of CM and CMM gene pairs was relatively
constant across tumor types (CM/CMM ratios were observed in
the range of 0.20–0.257; Supplementary Fig. S6). To evaluate the
impact of tumor purity on gene clustering, we further performed
purity-adjusted gene clustering using a partial correlation-based
gene-wise distancematrix, controlling for tumorpurity. According
to the coherence of cluster membership, we further discriminated
CM-D pairs (gene pairs whose cluster membership became dis-
cordant after purity adjustment) fromCMpairs and CMM-C pairs
(gene pairs whose cluster membership became concordant after
purity adjustment) from CMM pairs. We calculated CM-D/CM
and CMM-C/CMM ratios to evaluate the impact of tumor purity
on gene clustering (Fig. 3A). High CM-D/CM ratios (>0.55) were
observed for ACC, GBM, SCKM, and KICH, suggesting that more
than 55% of gene pairs belonging to the same cluster would be
assigned to different clusters after controlling for tumor purity.
Although CESC, LICH, KIRP, and COAD tumor types were
marked with low CM-D/CM ratios, a substantial number of CM
gene pairs (>20%) were still found as CM-D pairs for these tumor
types, suggesting that impact of tumor purity is substantial for
gene clustering overall. An additional measure of CMM-C/CMM
indicates the extent of how many gene pairs, which belong to
different clusters, would be assigned to the same cluster after
controlling for tumor purity. The CMM-C/CMM ratios were in the
range of 0.05 to 0.14 and correlated with the CM-D/CM ratios
(Fig. 3B), suggesting that CM-D/CM and CMM-C/CMM ratios
may serve as an indicator of which tumors are more vulnerable to
controlling for tumor purity in gene clustering.
To provide evidence for the need of purity adjustment, we
obtained PPI gene pairs from the HPRD database (27). The
frequency of PPI gene pairs was measured for four gene pair
categories (CM-C, CM-D, CMM-C, and CMM-D). The PPI gene
pairs were more frequent for CM-C and CMM-C compared with
CM-D and CMM-D (Fig. 3C). The elevated PPI gene pair frequen-
cies in concordant genepairs comparedwithdiscordant pairswere
largely consistent across tumor types (Supplementary Fig. S7),
supporting that purity adjustment increases the functional coher-
ence of gene clustering.
Figure 3.
The impact of tumor purity on gene
clustering. A, CM-D/CM and CMM-C/
CMM ratios are shown across 21 tumor
types (black and gray bars,
respectively). B, Scatter plot of the
CM-D/CM (x-axis) and CMM-C/CMM
(y-axis) ratios (r2 ¼ 0.81). C, Box plots
of the frequency of PPI gene pairs in
given gene pairs for four categories
(CM-C, CM-D, CMM-C, and CMM-D)
measured across 21 tumor types.
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Impact of tumor purity on gene expression–based molecular
taxonomy
It has been proposed that tumor purity may affect molecular
taxonomy or tumor subtyping, based on the gene expression (5).
This previous study demonstrated that the tumor purity was
substantially different across known tumor subtypes (e.g., low
tumor purity for GBM mesenchymal subtypes), and the correla-
tions of the feature genes (gene classiﬁers) with tumor purity are
distinct from overall correlations (e.g., bimodal distribution). In
this study, we further investigated the extent of association
between the feature genes representing individual tumor subtypes
and tumor purity, as well as their potential impact on the
expression-based molecular taxonomy. First, we observed that
the feature genes representing four GBM subtypes were either
signiﬁcantly correlated (proneural and classic subtypes) or
inversely correlated (neural and mesenchymal; P < 0.001; Kol-
mogorov–Smirnov tests; Fig. 4A). The unidirectional preference
of GBM feature genes toward either correlation or inverse corre-
lation may explain the previously observed bimodal distribution
of the correlation between GBM feature genes and tumor purity
when examined as aggregates (5). We further performed hierar-
chical clustering using the half of the feature genes that were either
correlated or inversely correlated with tumor purity (top 400
purity-correlated and 400 purity-inversely correlated feature
genes for Fig. 4B and C, respectively). The major perturbation in
molecular taxonomy (the split of subtype clusters) was observed
for the neural and proneural subtypes (blue and green in Fig. 4B
and C, respectively). These ﬁndings suggest that the molecular
taxonomy of GBM as well as the selection of feature genes may be
biased by tumor purity.
We further obtained the feature genes for an additional ﬁve
tumor types available for the annotations of mRNA expression-
based tumor subtypes (BRCA, COAD, HNSC, LUAD, and LUSC).
Feature genes representing three to four molecular subtypes per
tumor type were identiﬁed and examined for their correlation
with tumor purity. The extent of correlation or inverse correlation
is shown as the positive and negative normalized enrichment
scores, respectively (Fig. 4D). The feature genes representing
mesenchymal subtypes (GBM and HNSC) and SSM (stem/ser-
rated/mesenchymal) of COAD were substantially inversely cor-
related with the tumor purity, as well as the secretory subtype of
LUSC. The LUSC secretory subtype was characterized by over-
expression of secretory cell markers such as MUC1, as well as
immune markers such as NF-kB target genes (32). Feature genes
correlated with tumor purity included two classic subtypes of
GBM and HNSC, as well as subtypes associated with favorable
patient prognosis (proneural GBM subtype and luminal A BRCA
subtype). Four sets of feature genes representing classic and
mesenchymal subtypes of HNSC, SSM subtype of COAD, and
secretory subtype of LUSC are selected and shown for their
enrichment plots (Fig. 4E).
Discussion
In this study, we used a large-scale cancer transcriptome data-
base from the TCGA consortium comprising over 7,794 tumor
specimens and 21 tumor types. We investigated the impact of
tumor purity on the expression of genes and the related issues,
including the correlation between immune marker gene expres-
sion andmutation burdens, as well as gene clustering andmolec-
ular taxonomy. Because tumor purity is largely dependent on how
the tumor specimen is obtained, it has been debated whether
tumor purity represents biologically relevant, intrinsic tumor
features or simply represents systematic biases that are deter-
mined by extrinsic features, such as surgical resection and tissue
preparation. To distinguish the effects of intrinsic and extrinsic
features of tumor purity, one pioneering study evaluated the
correlation between hundreds of clinical features and tumor
purity (5). This study failed to identify a clear association with
the clinical features, and the authors concluded that tumor purity
differences are largely determined by extrinsic factors and that
tumor purity is a major confounding factor in cancer genome or
transcriptome analyses (5). Thus, it is challenging to examine the
potential impact of tumor purity on expression-based tumor
analyses such as the correlative analyses of immune gene expres-
sion with clinicopathologic features, as well as expression-based
gene clustering and molecular taxonomy.
Two main components of noncancerous tissues in tumor
specimens are stromal and immune cells. Their expression
showed comparable performance in the estimation of tumor
purity in a prior study (6). Presently, the extent of inverse corre-
lation with tumor purity was seen for the expression of immune
genes. Immune cell inﬁltrates and the expression of immune
marker genes have been highlighted as potential targets for
immunotherapy. The expression of immune-related genes, a
substantial fraction of which may be derived from tumor-inﬁl-
trating immune cells, has been assumed to be correlated with
tumor purity. Although anumber of in silicomethods are available
for the virtual microdissection of bulk tumor transcriptomes (23)
and also to estimate the abundance of immune cell inﬁltrates (7,
8), these deconvolution-based methodologies use a gene expres-
sionmatrix as an input, not dedicated to infer the origin of cells for
the expression of individual genes. Technologies developed for
discerning immune cell populations, such as conventional immu-
nohistochemistry and ﬂow cytometry combined with single-cell
sequencing, can be used to investigate the abundance and cell-
type–speciﬁc expression analyses (33). As demonstrated in a
study (34), single-cell, sequencing-based immune proﬁling may
alleviate the purity-associated biases. However, the issues of cost
and technical concerns remain (35). Although a unique setting,
such as patient-derived xenografts, enables the separation of
individual transcripts from the tumor and stromal cells (22), the
majority of tumor expression proﬁles are still obtained from bulk
tumormasses, and themain purpose of our studywas to highlight
the potential effects of tumor purity on conventional expression-
based analyses.We assumed that genes representative of cytotoxic
T lymphocytes (PRF1, GZMA, and CD8A) and immune check-
points (PDCD1, CD274, and CTLA4) may be a biased approach
due to the extrinsic nature of tumor purity. Our correlative
analyses revealed that immune-related genes comprise a major
gene category that was inversely correlated with tumor purity, and
the individual immune gene expression could be biased by tumor
purity, which should be taken into account when evaluating the
correlation with other clinicopathologic features including muta-
tion burdens. A number of studies have reported the correlation
between the expression of such immune-related genes and muta-
tion burdens (7, 15, 19, 36). However, our results suggest that
such correlationsmay also be biased by tumor purity. In this view,
the correlation between immune marker gene expression and
mutation burdens may be due to their correlation with tumor
purity. Genes whose expression is inversely correlated with tumor
purity will also correlate with mutation burdens to some extent,
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regardless of their biological functions. Immune gene expression
along withmutational burdens may be interdependent with each
other (15). However, it is expected that some of the observed
dependence between parameters may have arisen due to tumor
purity. The need to adjust tumor purity when evaluating the
correlation between immune gene expression or the abundance
of immune cell inﬁltrates with the mutation abundance has been
previously proposed (7, 36). The current ﬁndings provide solid
evidence by evaluating the correlation with or without control for
tumor purity.
A pioneering study on tumor purity previously described the
potential confounding effects of tumor purity in terms of coex-
pression network, molecular taxonomy, and differential expres-
sion between tumor and nontumor tissues (5). In this study, we
Figure 4.
The impact of tumor purity on the molecular taxonomy. A, Correlation of feature genes for four GBM subtypes with tumor purity. Enrichment towards high or low
correlation is indicated (right). P < 0.001 by Kolmogorov–Smirnov test. B and C, Hierarchical clustering of a subset of 400 feature genes correlated with
tumor purity (B), and 400 feature genes inversely correlated with tumor purity (C). Color bars above the heatmap represent four GBM subtypes (green: proneural,
blue: neural, orange: classic, and red: mesenchymal). D, For six tumor types (GBM, HNSC, BRCA, COAD, LUAD, and LUSC), the feature genes representing
three to four tumor subtypes of given tumor type were selected. Normalized enrichment scores, as the extent of enrichment toward correlation and inverse
correlationwith tumor purity, are shown. E, Four examples of classic (HNSC), SSM (COAD), secretory (LUSC), andmesenchymal (HNSC) subtypes are shown for their
enrichment of feature genes toward either correlated (left; high r) and inversely correlated (right; low r) with tumor purity as snapshots of enrichment plots
of GSEA output. Green line: running sum statistic to estimate enrichment score.
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examined the coherence of cluster membership for individual
gene pairs with or without controlling for tumor purity and also
investigated the correlation with tumor purity for feature genes
representing tumor subtypes. First, we observed that gene clus-
tering controlled for tumor purity can alter the cluster member-
ship for a substantial number of gene pairs. Speciﬁcally, ratios of
CM-D/CM and CMM-C/CMM gene pairs were observed in the
rage of 0.24 to 0.59 and 0.05 to 0.15, respectively. These two ratios
correlated with each other and varied across tumor types. For
example, in LUAD with high CM-D/CM and CMM-C/CMM
ratios, 53% of gene pairs that belong to the same cluster lost the
clustermembership concordance,whereas 14%of genepairswere
assigned to the same cluster after the purity adjustment. Even for
the tumor type with the lowest ratios such as CESC (CM-D/CM
and CMM-C/CMM ratios as 0.24 and 0.05, respectively), purity
adjustment substantially altered the cluster membership in gene
clustering. We also demonstrated that concordant gene pairs
(genes in pairs belonging to the same cluster after purity adjust-
ment) were more frequent in the number of PPI gene pairs,
suggesting that purity adjustment may improve the functional
coherence of gene clusters.
Next, we investigated the extent of correlation with tumor
purity for feature genes used for molecular taxonomy. We dem-
onstrated that feature genes representing the tumor subtypes were
often either correlated or inversely correlated with tumor purity.
As expected, inverse correlation with tumor purity was observed
for feature genes representing mesenchymal subtypes (COAD,
GBM, and HNSC). This is expected because stromal genes con-
stitute the major fraction of feature genes representing mesen-
chymal subtypes. Hierarchical clustering using a subset of feature
genes, either correlated or inversely correlated with the tumor
purity, showed certain subtypes (classic and mesenchymal GBM
subtypes) were relatively robust compared with other subtypes
(proneural and neural GBM subtypes), suggesting that the impact
of tumor purity may be context dependent. The feature genes
representing classic subtypes were correlated with tumor purity
for GBM and HNSC. We assumed that classic subtypes were
characterized by recurrent alterations of the corresponding tumor
types, such as 7p/q ampliﬁcations (GBM) and 3q ampliﬁcations
(HNSC), and that this representative nature of classic subtypes
may be responsible for the positive correlation of feature genes
with tumor purity. However, further investigation of why some
tumor subtypes with favorable prognosis (proneural/GBM and
luminal A/BRCA) shows positive correlation with tumor purity is
needed.
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